Omicron

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Against BioNTech SE (BNTX) and Urges BNTX Investors with Substantial Losses to Contact the Firm

Retrieved on: 
Monday, March 4, 2024
Class Action Lawsuit, Professional Services, Legal, Ladewig, Pfizer–BioNTech COVID-19 vaccine, ADS, Court, Person, BioNTech, Omicron, News, Fraud, CFTC, District court, Annual report, Lead, COVID-19, Medicare, IRS, BNTX, COVID, LLP, Cost, COPY, Pharmaceutical industry

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
  • The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Monday, February 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Medical Waste Management Market Worth $12.2 billion | MarketsandMarkets™

Retrieved on: 
Friday, March 8, 2024
Acquisition, European Commission, Triumvirate Environmental, Suez (company, 2015), Omicron, REMONDIS, Competition, Investment, Growth, Waste Management (company), Stericycle, Pulse, Waste management, Civil service commission, COVID-19, Developed country, Vigie, GRP, Biodegradable waste, Recycling, Research, Covanta, Market development, Pharmaceutical industry

Key Market Players of Medical Waste Management Industry:

Key Points: 
  • Key Market Players of Medical Waste Management Industry:
    The major players operating in this market are Veolia Environnement S.A. (France), Clean Harbors, Inc. (US), Stericycle Inc. (US), Waste Management, Inc. (US), Cleanaway Waste Management Limited (Australia), Casella Waste Systems, Inc. (US), Sharps Compliance, Inc. (US), Covanta Holding Corporation (US), Hazardous Waste Experts (US), REMONDIS SE & Co. KG.
  • (UK), BioMedical Waste Solutions, LLC (US), EcoMed Services (Canada), GRP & Associates, Inc. (US), BWS Incorporated (US), MEDPRO Disposal LLC (US), GIC Medical Disposal (Canada), Gamma Waste Services (US), Triumvirate Environmental (US), EPCO (Saudi Arabia), All Medical Waste Australia Pty Ltd. (Australia), Pro-Disposal Medical Waste Services (Georgia), SSO Medical Waste Management (US), Safeguard Waste Solutions (US), MedWaste Industries Inc. (US), DULSCO (UAE).
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1256
    Medical Waste Management Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall medical waste management market and the subsegments.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the medical waste management market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Veolia Environnement S.A. (France), Clean Harbors, Inc. (US), Stericycle Inc. (US), Waste Management, Inc. (US), Cleanaway Waste Management Limited (Australia), Casella Waste Systems, Inc. (US), Sharps Compliance, Inc. (US), among others in the medical waste management market strategies.

New CDC Respiratory Guidance Ignores Kidney Patient Concerns

Retrieved on: 
Thursday, March 7, 2024
Hospital, Dialysis, Infection, Kidney, HHS, Vaccine, Health, History, Organization, Kidney disease, Patient, Mortality, Kidney failure, Diabetes, Chronic kidney disease, Social media, Ageing, Loneliness, Transplant, Veterans' affairs, Emergency department, CDC, ESRD, Omicron, CDRH, COVID-19 vaccine, CKD, Safety, Hypertension, Congress, Disease, Monovalence, FDA, Friends, Food, Immunodeficiency, Risk, COVID-19, Read, Medicare, FMLA, Death, Control, COVID, Policy, Device, Science, Failure, Public

WASHINGTON, March 7, 2024 /PRNewswire/ -- Today, the American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, issued an Official Statement (appears below) in response to the Center for Disease Prevention and Control's (CDC) new Respiratory Virus Guidance, publicly announced on March 1, 2024. The CDC announcement occurred on the first day of National Kidney Month. March traditionally unites kidney stakeholders and people of goodwill in efforts to raise awareness of kidney diseases, address ongoing unmet patient needs, and advocate for removal of federal regulatory and payment barriers that impede access to, and development of, new kidney diagnostics, drugs, and devices.

Key Points: 
  • Mortality rates among kidney patients occurred at historic levels at the start of the COVID pandemic, devastated the kidney patient community and families, and this community's ongoing risks remain a strategic concern among patient advocates and allied kidney professionals.
  • AAKP also raised kidney patient health and safety concerns to CDC officials in stakeholder briefings prior to the March 1, 2024, CDC Respiratory Virus Guidance announcement.
  • The American Association of Kidney Patients (AAKP), the nation's largest and oldest independent kidney patient organization in the nation, is deeply concerned about the Center for Disease Prevention Control's (CDC) Respiratory Virus Guidelines, including for COVID, announced on March 1, 2024.
  • https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a5.htm
    Since 1969, The American Association of Kidney Patients has been a patient-led organization driving policy discussions on kidney patient care choice and medical innovation.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 15, 2024
Pfizer–BioNTech COVID-19 vaccine, Third Bridge, ADS, Court, The Company, BioNTech, Omicron, News, Food, Advertising, Risk, Woman, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

BNTX Securities Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE (BNTX) Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Tuesday, February 13, 2024
Ladewig, Pfizer–BioNTech COVID-19 vaccine, ADS, Court, Person, BioNTech, Omicron, News, Fraud, CFTC, District court, Annual report, Lead, COVID-19, Medicare, IRS, BNTX, COVID, LLP, Cost, COPY, Pharmaceutical industry

The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
  • We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
  • Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, February 12, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Cancer, Court, Biotechnology, Person, The Company, BioNTech, Omicron, Food, Complaint, Risk, COVID-19, BNTX, Infection, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points: 
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Sunday, February 11, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, Third Bridge, ADS, Pomerantz, Cancer, Court, Biotechnology, Person, BioNTech, Omicron, Prior, News, Food, Complaint, District court, Risk, Ext, Vaccination, EUR, COVID-19, BNTX, COVID, LLP, Infection, Action Replay, Cost, Research, Pharmaceutical industry

NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 8, 2024
Third Bridge, Vaccination, ADS, News, Food, The Company, Advertising, Woman, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Cost, BioNTech, Omicron, EUR, Risk, COVID, LLP, Research, BNTX, Court, Pharmaceutical industry

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Retrieved on: 
Tuesday, February 6, 2024
SARS-CoV-2, XBB 1.5, Antigen, Pfizer, Public, Immune system, Omicron, COVID-19, Patient, Safety, Biotechnology, MPH, GeoVax, Vaccine, MVA, Vaccination, Cancer, Labs, Infection, Capsid

ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced positive initial safety and immune response findings from its Phase 2 clinical trial at one month following administration of its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine (ClinicalTrials.gov Identifier: NCT04639466), was fully enrolled at the end of Sept 2023.

Key Points: 
  • The trial remains blinded to dose of vaccine received, with study subjects being followed for a total of one year.
  • To date, there have been no serious adverse events, and adverse events were in line with other routine vaccinations.
  • The immunological responses measured throughout the study period include both neutralizing antibodies against SARS-CoV-2 variants and specific T-cell responses.
  • We look forward to providing further updates regarding the successful progress of the clinical development of GEO-CM04S1.”